Neuronascent (NNI) discovers and develops therapies for depression, Down syndrome, post-traumatic stress disorder, Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Our lead candidate for each indication have shown great promise in several cell culture and disease models and show no sign of toxicity or other harmful effects. These, small-molecule, therapeutic candidates all promote new neurons from the brain’s own neuronal stem/progenitor cell populations. Preclinical studies of these candidates are currently under way, in-house and through contract laboratories, to complete the requirements for testing in humans.

Each NNI therapeutic candidate is uniquely optimized to increase neuron numbers in the brain, to improve critical function and to diminish loss of neurons due to disease progression. This ensures that each therapy is optimal for the indication.

NEWS & EVENTS

Sept 2012 – NeuroNascent Aims to Reverse Neurodegenerative Damage - Full BioWorld Today article available.

May 2012 – Dr. Kelleher-Andersson, the President and CSO of Neuronascent, Inc. presented at the annual Neurotechnology Industry Organization meeting in Boston. Kelleher-Andersson led off the Frontiers in Neurotech panel, by describing the large unmet need for disease modifying therapies to treat Alzheimer’s disease, post-traumatic stress disorder and Down syndrome, then suggested how Neuronascent’s first-in-class therapeutic candidates might address those unmet needs.

Mar 2012 – Patent claims were issued in South Korea for Neuronascent’s National patent application entitled “Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration”. Patent claims had previously been issued in the US and Russia back in 2011.

Feb 2012 – The founder and President of Neuronascent, Inc., Dr. Judith Kelleher-Andersson presented details of Neuronascent’s Alzheimer’s disease and Down syndrome pre-clinical therapeutic candidates at the 14th American Society for Experimental Neurotherapeutics conference in Washington, DC.

More News